Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sushma Ogram
08.23.22 -- Immunoassays & Successful Gene Therapy Commercialization
By Mathias Cousin, Ashraf Husain, and Shweta Arya, NextGen (Cell & Gene) Therapies Practice at Deloitte Rather than being seen as a secondary activity, immunoassays should be viewed as business-critical efforts with potential to create competitive advantage for gene therapy manufacturers.
Quantification Of Vector Genomic DNA And Residual DNA In Gene Therapy Vectors Using ddPCR
By Sushma A. Ogram, Small Scale and Assay Development and Analytics, Head, Thermo Fisher Scientific Capitalizing on advances in science and technology to help cure cancer and genetic diseases has led to significant growth of the cell and gene therapy (CGT) market.
11.03.21 -- The Essential Components Of A Sterility Assurance Program
By Crystal M. Booth, PSC Biotech The first step in developing a sterility assurance program is to list each step in the process, beginning at the point of use and ending in sterile storage. Each step should be evaluated for ways to prevent contamination in the manufacturing process or environments. This article shares the components of a holistic sterility assurance program for an aseptic manufactured product.
Quantification Of Vector Genomic DNA And Residual DNA In Gene Therapy Vectors Using ddPCR
By Sushma A. Ogram, Small Scale and Assay Development and Analytics, Head, Thermo Fisher Scientific Capitalizing on advances in science and technology to help cure cancer and genetic diseases has led to significant growth of the cell and gene therapy (CGT) market.
Quantification Of Vector Genomic DNA And Residual DNA In Gene Therapy Vectors Using ddPCR
By Sushma A. Ogram, Small Scale and Assay Development and Analytics, Head, Thermo Fisher Scientific Capitalizing on advances in science and technology to help cure cancer and genetic diseases has led to significant growth of the cell and gene therapy (CGT) market.
Quantification Of Vector Genomic DNA And Residual DNA In Gene Therapy Vectors Using ddPCR
By Sushma A. Ogram, Small Scale and Assay Development and Analytics, Head, Thermo Fisher Scientific Capitalizing on advances in science and technology to help cure cancer and genetic diseases has led to significant growth of the cell and gene therapy (CGT) market.
Digital Droplet PCR for Viral Vector Analysis
Polymerase chain reaction (PCR) is an essential tool for the analysis of therapeutic viral vectors used in cell and gene therapies. Digital droplet PCR (ddPCR) offers significant advantages over other qPCR methods, allowing for absolute, rather than relative, quantification of the target DNA molecules present in a sample, which is critical to a range of analytical assays necessary for viral vector production and characterization.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sushma
Contact Sushma, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack